SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted
by slower growth from syringes

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Preliminary
Results
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted
by slower growth from syringes

14.05.2024 / 18:19 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted
by slower growth from syringes

  * H1 24 revenues up 9% yoy at constant currencies to EUR 489m; EBITDA
    margin of 27.4% at constant currencies

  * FY 25 revenue growth projections impacted by lower demand for syringes
    from one customer

* Mid-term outlook confirmed

* Full set of Q2/H1 24 financial results to be published on June 27, 2024

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery
systems, continued its profitable growth trajectory in the first half of the
fiscal year 20241. From October to March, the company achieved revenues of
EUR 489m (H1 23: EUR 449m), corresponding to an increase of 9% at constant
currencies and a reported growth rate of 4%. Despite ongoing investments
into capacity expansions and a strong comparable base from the previous
year, EBITDA slightly increased by 2% to EUR 134m at constant currencies.
This development resulted in an EBITDA margin of 27.4% at constant
currencies (H1 23: 29.4%). Based on these figures, SCHOTT Pharma confirms
its guidance for the fiscal year 2024.

For the current fiscal year, the company forecasts organic revenue growth of
9% to 11% at constant currencies and an EBITDA margin at approximately prior
year's level. The forecasted growth is driven by the Drug Delivery Systems
(DDS) segment. The Drug Containment Solutions (DCS) segment is experiencing
industry-wide lower safety stock levels following the temporary destocking
effect for vials on the customer side.

In the first half of the year, SCHOTT Pharma consequently executed on its
strategy focusing on innovation and expansion. The company will continue to
pursue this strategic focus, which taps into some of the most important
pharma megatrends to further underline its dedication to growth.

"We are convinced that the long-term market dynamics are intact and that we
are well positioned with our strategy to continue benefitting from them.
This is evidenced by our good quarterly results. We are therefore
reiterating our guidance for the fiscal year 2024 as well as our mid-term
goals," said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma. "For the fiscal
year 2025, however, we expect slower growth than originally anticipated in
our syringe business, caused by lower demand from one customer. This will
have an impact on our overall revenue growth in FY 25."

SCHOTT Pharma learned that a large customer will reduce the needed
quantities of syringes from 2025 onwards. At the same time, the ongoing
stock optimization at customers in the DCS segment limits the potential for
immediate compensation. The company therefore expects a temporary impact on
revenue growth for the fiscal year 2025, also slowing the expansion of the
EBITDA margin. Due to these effects and a more conservative forecast
planning, SCHOTT Pharma assumes a revenue growth for the fiscal year 2025
within a high single to low double-digit percent range. This means that the
company's current expectations for that year are below the current market
consensus of high teens revenue growth.

SCHOTT Pharma expects the lower syringe demand to be only a temporary
effect. Given the intact long-term market dynamics, the company experiences
further interest from other customers in its drug delivery systems and
containment solutions. Therefore, the company foresees to compensate this
effect in the medium term. SCHOTT Pharma confirms its mid-term guidance of
organic revenue growth above 10% CAGR and an EBITDA margin in the low 30%
range, at constant currencies.

SCHOTT Pharma will publish its full set of financials for Q2 24 on June 27,
2024.

For additional news about SCHOTT Pharma please visit our media center.

Key figures Q2 24

    (in EUR m)            Q2 23 Q2 24   yoy  Q2 24 (cc2)  yoy (cc2)
    Revenues               224   234    +5%       247        +11%
    EBITDA                 69    44    -35%       67          -3%
    EBITDA margin (in %)  30.7% 18.9% -11.8pp    26.9%      -3.8pp

Key figures H1 24

    (in EUR m)            H1 23 H1 24  yoy  H1 24 (cc2)  yoy (cc2)
    Revenues               449   466   +4%       489         +9%
    EBITDA                 132   117   -11%      134         +2%
    EBITDA margin (in %)  29.4% 25.1% -4.3pp    27.4%      -2.0pp

1The fiscal year runs from October to September. H1 2024 therefore relates
to the period from October 2023 to March 2024.

2cc = at constant currencies

All stated 2024 figures are unaudited.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded
in science to ensure that medications are safe and easy to use for people
around the world. The portfolio comprises drug containment solutions and
delivery systems for injectable drugs ranging from prefillable glass and
polymer syringes to cartridges, vials, and ampoules. Every day, a team of
over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute
to global healthcare. The company is represented in all main pharmaceutical
hubs with 16 manufacturing sites in Europe, North and South America, and
Asia. With over 1,000 patents and technologies developed in-house and a
state-of-the-art R&D center in Switzerland, the company is focused on
developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is
headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange
as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl
Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to
sustainable development for society and the environment and has the
strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma
has over 1,800 customers including the top 30 leading pharma manufacturers
for injectable drugs and generated revenue of EUR 899 million in the fiscal
year 2023.

Press contact

Joana Kornblum

Media Relations

Tel.: +49 151/29223552

E-Mail: joana.kornblum@schott.com

Jasko Terzic, CFA

Investor Relations

E-Mail: ir.pharma@schott.com


---------------------------------------------------------------------------

14.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SCHOTT Pharma AG & Co. KGaA
                   Hattenbergstraße 10
                   55122 Mainz
                   Germany
   ISIN:           DE000A3ENQ51
   WKN:            A3ENQ5
   Indices:        SDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate
                   Exchange; Vienna Stock Exchange
   EQS News ID:    1903113

End of News EQS News Service
---------------------------------------------------------------------------

1903113 14.05.2024 CET/CEST